Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedMay 04, 2026
DataAggregated Company Financials
Companies20
  • 7D5.1%
  • 3M-23.2%
  • 1Y-34.1%
  • YTD-15.8%

The Healthcare industry is up 5.1% in the last week, with Novo Nordisk up 6.9%. In contrast, the industry has lost 34% in the last 12 months. Earnings are forecast to grow by 3.4% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 04 May 2026DKK 1.6tDKK 447.5bDKK 130.0b18.6x12.6x3.7x
Wed, 01 Apr 2026DKK 1.4tDKK 447.7bDKK 130.0b17.3x11x3.2x
Fri, 27 Feb 2026DKK 1.5tDKK 447.7bDKK 131.0b18.5x11.4x3.3x
Sun, 25 Jan 2026DKK 2.3tDKK 453.5bDKK 136.8b18.4x16.7x5x
Tue, 23 Dec 2025DKK 1.8tDKK 453.7bDKK 136.9b16.9x13.5x4.1x
Thu, 20 Nov 2025DKK 1.9tDKK 454.3bDKK 137.1b16.9x13.7x4.1x
Sat, 18 Oct 2025DKK 2.0tDKK 447.5bDKK 141.7b19x14.4x4.5x
Mon, 15 Sep 2025DKK 2.0tDKK 447.3bDKK 141.7b19.9x14.4x4.6x
Wed, 13 Aug 2025DKK 1.9tDKK 434.7bDKK 132.4b29x14.1x4.3x
Fri, 11 Jul 2025DKK 2.5tDKK 423.1bDKK 124.5b30.3x19.9x5.9x
Sun, 08 Jun 2025DKK 2.7tDKK 423.8bDKK 124.7b30.7x21.3x6.3x
Tue, 06 May 2025DKK 2.5tDKK 409.3bDKK 121.3b22.3x20.7x6.1x
Thu, 03 Apr 2025DKK 2.5tDKK 409.5bDKK 121.3b23.3x20.8x6.2x
Sat, 01 Mar 2025DKK 3.4tDKK 410.1bDKK 121.4b28.6x27.9x8.3x
Mon, 27 Jan 2025DKK 3.3tDKK 387.4bDKK 111.3b29.4x29.8x8.6x
Wed, 25 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.7x29.5x8.5x
Fri, 22 Nov 2024DKK 3.8tDKK 387.4bDKK 111.3b31.2x33.8x9.7x
Sun, 20 Oct 2024DKK 4.2tDKK 372.1bDKK 107.2b37.1x38.8x11.2x
Tue, 17 Sep 2024DKK 4.7tDKK 371.9bDKK 107.1b36.5x44x12.7x
Thu, 15 Aug 2024DKK 4.6tDKK 370.3bDKK 106.9b36.8x43.4x12.5x
Sat, 13 Jul 2024DKK 4.9tDKK 355.2bDKK 106.2b35.5x46.6x13.9x
Mon, 10 Jun 2024DKK 4.9tDKK 355.3bDKK 106.2b36.2x46.5x13.9x
Wed, 08 May 2024DKK 4.5tDKK 355.3bDKK 106.5b35x42.3x12.7x
Fri, 05 Apr 2024DKK 4.4tDKK 341.2bDKK 99.6b38x44.4x13x
Sun, 03 Mar 2024DKK 4.4tDKK 340.0bDKK 98.9b38x44.4x12.9x
Tue, 30 Jan 2024DKK 3.8tDKK 320.5bDKK 90.0b33.7x42.7x12x
Thu, 28 Dec 2023DKK 3.6tDKK 320.4bDKK 90.0b33.1x40x11.2x
Sat, 25 Nov 2023DKK 3.7tDKK 320.5bDKK 90.0b32.8x41.2x11.6x
Mon, 23 Oct 2023DKK 3.5tDKK 305.5bDKK 82.2b27.8x42.6x11.5x
Wed, 20 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b35.4x41.7x11.2x
Fri, 18 Aug 2023DKK 3.4tDKK 302.9bDKK 81.1b37.7x41.6x11.1x
Sun, 16 Jul 2023DKK 2.9tDKK 286.9bDKK 75.4b39x38.6x10.1x
Tue, 13 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.1x40x10.5x
Thu, 11 May 2023DKK 3.1tDKK 285.5bDKK 74.7b41x42.1x11x
Price to Earnings Ratio

42.1x


Total Market Cap: DKK 3.1tTotal Earnings: DKK 74.7bTotal Revenue: DKK 285.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 30.8x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 12.6x which is lower than its 3-year average PE of 30.9x.
  • The 3-year average PS ratio of 8.8x is higher than the industry's current PS ratio of 3.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 20% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market2.43%
Healthcare5.08%
Pharma6.57%
Healthtech2.13%
Healthcare Services1.01%
Life Sciences0.016%
Biotech-0.29%
Medical Equipment-1.17%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 601x.
    • Analysts are expecting annual earnings growth of 87.6%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthcare Services industry, expecting annual earnings growth of 88% over the next 5 years.
  • This is better than its past earnings decline of 100% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 8.6% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
NOVO B Novo NordiskDKK 278.006.9%
+DKK 79.4b		-39.0%PE12x
ALK B ALK-AbellóDKK 242.007.2%
+DKK 3.6b		55.3%PE44.8x
DEMANT DemantDKK 209.001.9%
+DKK 801.4m		-15.8%PE18.6x
ZEAL Zealand PharmaDKK 309.001.9%
+DKK 402.5m		-36.4%PE3.4x
BIOPOR BioPortoDKK 1.2427.6%
+DKK 132.7m		-21.5%PS15.2x

Latest News

ZEAL
DKK 309.00
Zealand Pharma
7D
1.9%
1Y
-36.4%
NOVO B
DKK 278.00
Novo Nordisk
7D
6.9%
1Y
-39.0%

NOVO B: Higher Discount Rate Will Pressure Long Term Cash Flows

The updated analyst price target for Novo Nordisk has been revised from DKK 340.00 to DKK 184.09. Analysts attribute this change to a higher discount rate, softer revenue growth assumptions, slightly lower profit margins, and a reduced future P/E estimate.
BAVA
DKK 188.00
Bavarian Nordic
7D
0.7%
1Y
17.8%

BAVA: Vaccine Approvals And Capacity Expansion Will Drive Future Upside

Analysts have kept their DKK 250.00 price target for Bavarian Nordic unchanged. They point to only small tweaks to assumptions on discount rate, revenue contraction, profit margin and future P/E, which they view as largely offsetting each other.
EMBLA
DKK 26.75
Embla Medical hf
7D
-4.5%
1Y
-7.9%

EMBLA: Share Cancellations And Capital Authorisations Will Support Future Upside

Analysts have trimmed their price target on Embla Medical hf. to DKK 33.30 from DKK 37.40, citing updated assumptions around a slightly higher discount rate, more moderate revenue growth of 8.40% and a lower future P/E of about 21x, while keeping profit margin expectations broadly in line.
COLO B
DKK 402.80
Coloplast
7D
-2.5%
1Y
-42.2%
GMAB
DKK 1,694.00
Genmab
7D
-1.0%
1Y
19.2%

GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook

Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.
GUBRA
DKK 321.00
Gubra
7D
0.5%
1Y
-22.0%
ALK B
DKK 242.00
ALK-Abelló
7D
7.2%
1Y
55.3%
DEMANT
DKK 209.00
Demant
7D
1.9%
1Y
-15.8%

DEMANT: 2026 EBIT Guidance May Support Re Rating Despite Mixed Research

Analysts have adjusted their price target for Demant slightly lower to DKK 229.83 from DKK 232.44. This reflects a mix of recent target increases and cuts across major banks, as well as a modest recalibration of fair value, discount rate, revenue growth, profit margin and future P/E assumptions.
CHEMM
DKK 326.00
ChemoMetec
7D
-0.4%
1Y
-33.0%
AMBU B
DKK 65.45
Ambu
7D
0.6%
1Y
-45.9%

AMBU B: Reset P/E Assumptions Will Support Future Upside Repricing

Ambu's analyst price target has been reduced by DKK 12 to reflect updated views on its P/E assumptions, revenue growth profile and profitability, with analysts pointing to the recent DKK 12 target cut cited in Street research. Analyst Commentary JPMorgan's DKK 12 reduction in its Ambu price target reflects a reset of P/E expectations and a more cautious stance on the company's revenue growth and profitability profile.
HLUN B
DKK 42.40
H. Lundbeck
7D
-4.3%
1Y
32.1%

HLUN B: Dividend Policy And Neuroscience Pipeline Will Support Balanced Medium Term Outlook

Analysts have kept their DKK 46.13 price target for H. Lundbeck unchanged, citing consistent assumptions about revenue growth, profit margins and future P/E as the basis for their view.
BIOPOR
DKK 1.24
BioPorto
7D
27.6%
1Y
-21.5%